华大智造：拟出售CGI 100%股权及授权相关知识产权

Core Viewpoint - The company BGI Genomics announced that its wholly-owned subsidiary MGI R&D HK plans to sell 100% equity of CGI to SwissRockets after divesting related assets and liabilities by February 11, 2026, with an initial payment at closing and final payment within 12 months thereafter [1] Group 1: Transaction Details - MGI US LLC will license StandardMPS sequencing technology and universal sequencing technology to SwissRockets for compensation [1] - CGI will reverse license relevant intellectual property back to MGI [1] Group 2: Financial Impact - CGI's projected revenues for 2024 and 2025 are estimated at 287 million yuan and 304 million yuan, respectively [1] - The net loss for CGI in 2025 is projected to be 103 million yuan [1] - The transaction is not expected to have a material adverse effect on the company's main business and financials [1]